Stryker (SYK) to Acquire Trauson in $764M All-Cash Deal
Get Alerts SYK Hot Sheet
Price: $321.68 -0.65%
Overall Analyst Rating:
SELL (= Flat)
Dividend Yield: 1.1%
Revenue Growth %: +10.4%
Overall Analyst Rating:
SELL (= Flat)
Dividend Yield: 1.1%
Revenue Growth %: +10.4%
Join SI Premium – FREE
Stryker Corporation (SYK) and Trauson Holdings Company Limited announced that Stryker will make a voluntary general offer to acquire all the shares of Trauson for HK$7.50 per ordinary share for a total consideration of $764 million in an all cash transaction, representing an enterprise value of approximately $685 million. Trauson`s controlling shareholder, Luna Group, has undertaken to accept the offer from Stryker by tendering 61.7% of the Trauson shares towards the offer. Founded in China in 1986 by Chairman Fuqing Qian, Trauson had sales in 2011 approximating $60 million and is the leading trauma manufacturer in China and a major competitor in the spine segment. Stryker and Trauson have maintained a relationship under an OEM agreement for instrumentation sets since 2007. With this acquisition, Stryker will expand its presence in a key emerging market with a product portfolio and pipeline that is targeted at the large and fast growing value segment of the Chinese orthopaedic market.
The closing of the transaction is subject to customary conditions. Upon closing, the transaction is expected to be neutral to Stryker`s 2013 diluted net earnings per share excluding acquisition and integration-related charges and accretive thereafter. The transaction is expected to close by the end of the second quarter of 2013.
Barclays Capital served as Stryker`s exclusive financial advisor and Sullivan & Cromwell served as outside legal counsel for Stryker in connection with this transaction.
The closing of the transaction is subject to customary conditions. Upon closing, the transaction is expected to be neutral to Stryker`s 2013 diluted net earnings per share excluding acquisition and integration-related charges and accretive thereafter. The transaction is expected to close by the end of the second quarter of 2013.
Barclays Capital served as Stryker`s exclusive financial advisor and Sullivan & Cromwell served as outside legal counsel for Stryker in connection with this transaction.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Gap taps Coach architect Reed Krakoff for $29.95-$498 handbag line
- Yum! Brands completes Pizza Hut sale to LongRange for $1.5B
- Designer Brands (DBI) PT Lowered to $6 at UBS
Create E-mail Alert Related Categories
Corporate News, FDA, Mergers and AcquisitionsRelated Entities
Barclays, EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share